Tyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma.

Phase 2 Unknown 53 enrolled China Medical University, China

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of fruquintinib or regorafenib in combination with anti-PD-1 antibody in TKI (fruquintinib or regorafenib)-responded MSS/pMMR metastatic colorectal adenocarcinoma.

Timeline

Start: 2020-07-24
Primary completion: 2022-07-31
Completion: 2022-07-31

Publications

Dong Q, Diao Y, Sun X, Zhou Y, Ran J, Zhang J. Evaluation of tyrosine kinase inhibitors combined with antiprogrammed cell death protein 1 antibody in tyrosine kinase inhibitor-responsive patients with microsatellite stable/proficient mismatch repair metastatic colorectal adenocarcinoma: protocol for open-label, single-arm trial. BMJ Open. 2022 Apr 4;12(4):e049992. doi: 10.1136/bmjopen-2021-049992.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Fruquintinib	Small molecule	5 mg	Oral
Subject	Regorafenib	Small molecule	120 mg	Oral
Subject	Toripalimab	Monoclonal antibody	240 mg	Other

Tyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma.

Summary

Timeline

Publications

Drugs

Indications